Filtrer vos résultats
- 3
- 2
- 1
- 3
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trialthe 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩
Communication dans un congrès
hal-01632415v1
|
||
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialEuropean Journal of Cancer, 2018, 104, pp.108-116. ⟨10.1016/j.ejca.2018.09.006⟩
Article dans une revue
hal-01960176v1
|
|||
|
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)Journal of Clinical Oncology, 2020, 38 (15), pp.1702-1710. ⟨10.1200/JCO.19.01960⟩
Article dans une revue
hal-02677109v1
|